Teleflex is launching new products, acquiring Biotronik’s vascular unit, and splitting into two companies to reignite growth.
Benign prostatic hyperplasia (BPH) is increasingly prevalent with advancing age, affecting approximately 50% of men aged over 50 years and rising to over 80% by the eighth decade of life 1.
Dear Dr. Roach: I am 71 and began having urinary issues due to benign prostatic hyperplasia (BPH) many years ago. I took alpha blockers (Flomax, double Flomax and tadalifil), which didn't provide any ...
ProVerum has raised $80 million in venture capital funding to complete the development of its minimally invasive, stentlike implant to relieve the urinary symptoms of an enlarged prostate. Known as ...
ProVerum announced today that it closed an $80 million Series B equity financing to support its device to treat benign prostatic hyperplasia (BPH). MVM Partners led the financing. New investors ...
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- ProVerum Limited, the developer of the ProVee® System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH), announced today the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback